TAJ-β inhibitors represent a specialized class of chemical compounds designed to specifically inhibit the function of the TAJ-β protein, a molecule known to play a role in various cellular regulatory pathways. TAJ-β inhibitors operate by binding to the active sites or key functional domains of the TAJ-β protein, thus preventing its normal activity within the cell. These inhibitors are often developed to fit the precise structural features of the TAJ-β protein, ensuring that they can effectively block its interactions or catalytic actions. The inhibitors may target different regions of the protein, such as its binding pockets or allosteric sites, depending on their mode of action and the specific mechanism by which they interfere with the protein's function. The chemical design of TAJ-β inhibitors is crucial for achieving a high degree of specificity, ensuring they interact with TAJ-β while minimizing interaction with other proteins.
TAJ-β inhibitors are synthesized using advanced organic synthesis techniques that allow the precise assembly of molecules with defined structural features. These compounds often feature a combination of hydrophobic and hydrophilic regions that are designed to complement the three-dimensional shape of the TAJ-β protein. Some inhibitors may include functional groups capable of forming strong covalent or non-covalent bonds with the protein's active sites, thereby enhancing their inhibitory potency. The solubility, stability, and reactivity of these inhibitors are carefully considered during their design, as these properties influence how effectively the inhibitor can interact with TAJ-β under different conditions. The diversity in the structural composition of TAJ-β inhibitors allows for the fine-tuning of their binding affinities, making them a valuable class of compounds for studying the biochemical functions and regulatory mechanisms associated with the TAJ-β protein.
Items 1 to 10 of 11 total
画面:
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPKを阻害し、TAJ-βが関与する炎症反応経路に影響を及ぼす可能性がある。 | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K阻害剤は、細胞の生存と増殖に重要なシグナル伝達経路を破壊する可能性がある。 | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK阻害剤は、TAJ-β活性に関連するストレス応答経路やアポトーシスに影響を与えるかもしれない。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK阻害剤は、MAPK/ERK経路に影響を与える可能性があり、TAJ-βの機能に関連する可能性がある。 | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
もう一つのPI3K阻害剤は、TAJ-βが関与すると考えられているシグナル伝達経路にさらに影響を与える可能性がある。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR阻害剤は、TAJ-βに関連する細胞増殖とオートファジーのプロセスを調節するかもしれない。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAFキナーゼ阻害剤は、TAJ-βが関与する細胞増殖・分化経路に影響を与える可能性がある。 | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
汎カスパーゼ阻害剤であり、TAJ-βが制御するアポトーシス経路に影響を与える可能性がある。 | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
プロテアソーム阻害剤は、TAJ-βの機能に関連するタンパク質分解経路に影響を与える可能性がある。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
NF-κBやその他のシグナル伝達分子を調節し、炎症や細胞増殖に影響を与える可能性がある。 | ||||||